Complete or incomplete coronary revascularisation in patients with myocardial infarction and multivessel disease: a propensity score analysis from the “real-life” BleeMACS (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome) registry

EuroIntervention 2017;13:407-414 published online February 2017. DOI: 10.4244/EIJ-D-16-00350

Giorgio Quadri
Giorgio Quadri1*, MD; Fabrizio D’Ascenzo1, MD; Claudio Moretti1, MD; Maurizio D’Amico1, MD; Sergio Raposeiras-Roubín2, MD; Emad Abu-Assi2, MD; Jose Paulo Simao Henriques3, MD; Jorge Saucedo4, MD; José Ramón González-Juanatey5, MD; Stephen B. Wilton6, MD; Wouter J. Kikkert3, MD; Iván Nuñez-Gil7, MD; Albert Ariza-Sole8, MD; Xiantao Song9, MD; Dimitrios Alexopoulos10, MD; Christoph Liebetrau11, MD; Tetsuma Kawaji12, MD; Zenon Huczek13, MD; Shao-Ping Nie
1. Dipartimento di Scienze Mediche, Divisione di Cardiologia, Città della Salute e della Scienza, Turin, Italy; 2. University Hospital Álvaro Cunqueiro, Vigo, Spain; 3. University Academic Medical Center, Amsterdam, the Netherlands; 4. NorthShore Universi

Aims: The benefit of complete or incomplete percutaneous coronary intervention (PCI) in patients with myocardial infarction and multivessel disease remains debated. The aim of our study w

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

multiple vessel diseasenon-st-segment elevation myocardial infarction (nstemi)st-segment elevation myocardial infarction (stemi)
Coronary interventionsSTEMINSTEMILeft main and multivessel diseaseVascular access and bleedingVascular access and bleedingVascular access and bleeding
Read next article
First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial

Latest news